Biopharma financings more than doubled in the first half of 2026, reaching $59.76 billion across 567 deals, according to an analysis of public, private, and other financings. The total compares with $29.53 billion across 501 transactions in the first half of 2025. The report attributes the jump largely to renewed follow-on activity, which accounted for roughly half of proceeds, indicating investors are returning to later-stage confidence rather than only early-stage exploration. June alone closed the quarter with $10.32 billion raised across 99 transactions. The pattern of increased follow-on support is likely to influence how early-stage biotechs plan for milestone execution and how investors calibrate risk across the pipeline. Overall, the financing acceleration suggests market participants are re-pricing biotech exposure as deal activity approaches recent highs.